STOCK TITAN

Teva Pharmaceutical Industries Limited - $TEVA STOCK NEWS

Welcome to our dedicated page for Teva Pharmaceutical Industries news (Ticker: $TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharmaceutical Industries stock.

Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) is a leading Israeli multinational pharmaceutical company headquartered in Tel Aviv, Israel. As the world's largest generic drug manufacturer, Teva plays a pivotal role in the global healthcare industry. The company derives approximately 50% of its sales from North America, contributing significantly to the total number of generic prescriptions in the United States.

Teva's extensive portfolio includes not only generic drugs but also active pharmaceutical ingredients (APIs) and proprietary pharmaceuticals. The company's operations are categorized into three main therapeutic areas:

  • Central Nervous System (CNS): Featuring notable products such as Copaxone, Ajovy, and Austedo, Teva addresses critical CNS disorders with innovative treatments.
  • Respiratory: Products like Qvar and ProAir contribute to Teva's robust respiratory medicine lineup, catering to patients with various respiratory conditions.
  • Oncology: Teva's oncology portfolio includes groundbreaking medicines such as Truxima, Herzuma, and Bendeka/Treanda, providing essential treatments for cancer patients.

In addition to its pharmaceutical products, Teva is a major player in active pharmaceutical ingredients, offering contract manufacturing services and owning Anda, a U.S.-based distributor of generic and specialty drugs.

Teva's global presence extends beyond North America, with significant operations in Europe, Japan, Russia, and its home country, Israel. The company's strategic partnerships and innovations keep it at the forefront of the pharmaceutical industry. Recent developments include advancements in biosimilars and innovative treatments.

Financially, Teva continues to maintain a strong position, focusing on growth and resilience amidst market challenges. The company is committed to improving patient health worldwide by providing high-quality, affordable medicines.

Rhea-AI Summary

Teva Pharmaceutical Industries announced that its President and CEO, Richard Francis, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024. The presentation is scheduled to begin at 8:00 A.M. Eastern Time. A live webcast of the presentation will be available on Teva's Investor Relations website, with an archived version accessible within 24 hours post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
conferences
-
Rhea-AI Summary

Teva Pharmaceuticals presented new data at the Psych Congress Elevate 2024 regarding UZEDY® (risperidone), an extended-release injectable suspension for treating schizophrenia. Key findings include that switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provides a comparable pharmacokinetic (PK) profile. Additional Phase 3 RISE and SHINE studies showed no new safety concerns in young adults. The Global ADVANCE survey revealed real-world insights from healthcare professionals, caregivers, and patients on long-acting injectable (LAI) treatments. UZEDY can be administered subcutaneously without a loading dose, offering convenience and relapse prevention.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Teva Pharmaceuticals presented interim results from the Phase 4 IMPACT-TD Registry study at Psych Congress Elevate 2024, revealing that tardive dyskinesia (TD) significantly impacts patients' quality of life. The study involves 286 patients and shows that 98% of them experience TD's effects in daily life, with 83% facing moderate to severe impacts. Key findings include that TD affects social, psychological, and physical aspects even in mild cases. The study also evaluated the effectiveness of AUSTEDO XR and AUSTEDO tablets in treating TD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Teva Pharmaceuticals announced that the U.S. FDA has approved AUSTEDO XR, an extended-release, once-daily tablet for treating tardive dyskinesia (TD) and Huntington’s disease (HD) chorea, available in four dosages (30, 36, 42, 48 mg). This approval offers flexibility and convenience for patients, with symptom improvement expected as early as two weeks for TD and significant reduction in chorea symptoms for HD. AUSTEDO XR is the only VMAT2 inhibitor without restrictions for use with CYP3A4/5 inducers or inhibitors. Over 90% of patients with insurance coverage will pay $10 or less for their prescription with financial assistance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
-
Rhea-AI Summary

Teva Pharmaceutical Industries announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations, effective June 3, 2024. Shields succeeds Eric Drapé and will be based in Parsippany, NJ. Shields brings over 25 years of experience in biopharmaceutical and animal health industries, having held significant roles at Merck, Sanofi, and Amgen. At Merck, he supported $5.6 billion in annual sales and drove operational improvements. Teva CEO Richard Francis highlighted Shields' expertise as vital for the company's growth strategy. Drapé, who significantly contributed to Teva's operational agility and margin improvements, will depart after 11 years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
management
-
Rhea-AI Summary

Teva reported Q1 2024 revenues of $3.8 billion, a 5% increase from Q1 2023, with growth in generics business and AUSTEDO. AJOVY revenues were up 18%. Positive Phase 3 results for olanzapine LAI (TEV' 749). Financial outlook reaffirmed for 2024. Gross profit increased by 12%. Non-GAAP diluted EPS was $0.48. Cash flow used in operating activities was $124 million. Debt decreased to $19,643 million. US segment revenues increased by 3%, led by AUSTEDO and generic products. Europe segment revenues grew by 7%, driven by generic products and AJOVY.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.83%
Tags
Rhea-AI Summary

Teva Pharmaceuticals and Medincell have announced positive Phase 3 efficacy results from the SOLARIS trial evaluating TEV-‘749 (olanzapine) as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia. The study met its primary endpoint, showing significant reductions in the PANSS total score across all dose groups compared to placebo. TEV-‘749 was well tolerated with no PDSS observed. The drug utilizes SteadyTeq™ technology, a copolymer technology proprietary to Medincell. The results demonstrate the potential of TEV-‘749 as an effective long-acting treatment option for schizophrenia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.83%
Tags
-
Rhea-AI Summary

Teva Pharmaceutical Industries announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on May 14, 2024. The presentation will be available via live webcast on Teva’s Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences
-
Rhea-AI Summary

Teva Pharmaceutical Industries released its 2023 Healthy Future Report, outlining a renewed sustainability strategy focused on achieving net zero emissions, renewable electricity, and health system strengthening. The report highlights the issuance of $2.49 billion in sustainability-linked bonds, bringing the total to $7.5 billion, making Teva the largest issuer in pharmaceuticals globally. Teva's efforts in access to medicines, greenhouse gas emission reductions, supplier engagement, and community support are detailed. The report reflects Teva's commitment to sustainability, business integrity, and social responsibility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
Rhea-AI Summary
Teva Pharmaceuticals presents final results from the Phase 4 START study at the 2024 AAN Annual Meeting, confirming the effectiveness, safety, adherence, and patient satisfaction with the 4-week Titration Kit for AUSTEDO in treating Huntington's disease chorea.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none

FAQ

What does Teva Pharmaceutical Industries Limited specialize in?

Teva specializes in generic drugs, active pharmaceutical ingredients, and proprietary pharmaceuticals.

Where is Teva headquartered?

Teva is headquartered in Tel Aviv, Israel.

What are some of Teva's key products?

Key products include Copaxone, Ajovy, Austedo, Qvar, ProAir, Truxima, Herzuma, and Bendeka/Treanda.

In which regions does Teva operate?

Teva operates in North America, Europe, Japan, Russia, and Israel.

How much of Teva's sales come from North America?

Approximately 50% of Teva's sales come from North America.

What therapeutic areas does Teva focus on?

Teva focuses on central nervous system, respiratory, and oncology therapeutic areas.

What is Anda?

Anda is a U.S.-based distributor of generic and specialty drugs owned by Teva.

Does Teva offer contract manufacturing services?

Yes, Teva offers contract manufacturing services.

What role does Teva play in the U.S. generic prescription market?

Teva accounts for a high-single-digit percentage of the total number of generic prescriptions in the U.S.

What recent advancements has Teva made?

Teva has made advancements in biosimilars and innovative treatments across its therapeutic areas.

Teva Pharmaceutical Industries Limited

NYSE:TEVA

TEVA Rankings

TEVA Stock Data

19.27B
1.12B
53.13%
1.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
TEL AVIV